Pfizer's stock is down roughly 60% from its late 2021 highs, but the drug giant is working to innovate its way back into the big leagues.

Within Pfizer’s large product portfolio, several mixed product trends led to overall 4% year-over-year growth, with particularly strong sales in vaccines and cancer drugs offsetting declines from ...

Pfizer (NYSE: PFE) has been around for 175 years, selling a wide range of drugs in various treatment areas over time. But this pharma giant truly became a household name a few years ago. Pfizer made ...

If you are wondering whether Pfizer at around $25 a share is a value trap or a genuine opportunity, this breakdown will help you decide whether it deserves a spot on your watchlist right now. Despite ...

Explore the exciting world of Pfizer (NYSE: PFE) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...

Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...

We regret to report that long term Pfizer Inc. (NYSE:PFE) shareholders have had that experience, with the share price ...

Pfizer enters the new year as a company in transition, but one with a heavily fortified bottom line. Management has set a revenue floor of approximately $61 billion for 2026. This is a realistic, ...

Pfizer's stock has dropped due to a decline in revenues post-COVID, presenting a value investment opportunity. The company still generates significant gross profit and has a strong revenue growth rate ...

ALEXANDRIA, VA (June 17, 1999)-- Pfizer (NYSE: PFE) is trading at 38 times its trailing 12-month earnings per share, 40 times 1999 estimates, and 33.9 times the year 2000 EPS guess. The largest ...